 If at any dose level, two or more patients experience a DLT the previous dose level will be considered as the maximum tolerated dose MTD. An additional three patients for a total of six patients will then be treated at the MTD. If less than two patients experience a DLT this dose level will be established as the MTD. The phase II aspect is designed in a Simon II stage format in which to satisfy our study powering, the first stage there will be 10 patients enrolled. If there are 2 or more successful treatments in that group negative urine cytology and bladder biopsy after 6 months, then the first stage will pass the rejection rule, and up to another 19 patients will be enrolled. If at any point in the study, there have been a total of 6 or more successes, then the phase II aspect will be considered a successful trial and the study will be completed at that point. 